Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H1 2018

March 2018 | 73 pages | ID: PEE54C94F35EN
Global Markets Direct

Abstracts

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H1 2018

SUMMARY

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 12 molecules. The latest report Placenta Growth Factor - Pipeline Review, H1 2018, outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration.

It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 2, 5 and 3 respectively.

Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular/Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Choroidal Neovascularization, Retinal Vein Occlusion, Diabetic Nephropathy, Macular Edema, Medulloblastoma, Myopia, Neovascular Glaucoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy and Retinopathy.

Furthermore, this report also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
• The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects
• The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Overview
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Companies Involved in Therapeutics Development
Alteogen Inc
Benitec Biopharma Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Coherus BioSciences Inc
Formycon AG
Lupin Ltd
Regeneron Pharmaceuticals Inc
ThromboGenics NV
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Drug Profiles
(aflibercept + nesvacumab) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BB-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
conbercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-188 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THR-317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ziv-aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Dormant Products
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Discontinued Products
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Product Development Milestones
Featured News & Press Releases
Mar 19, 2018: EYLEA (aflibercept) Injection Demonstrates Positive Top line Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial
Feb 13, 2018: Bayer Receives First Approval for Eylea in China
Feb 12, 2018: New data for aflibercept show prolonged injection intervals
Dec 21, 2017: Bayer Yakuhin Announces Results on EYLEA at the 11th Asia Pacific Retinal Vitreological Society (APVRS)
Dec 11, 2017: Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA (aflibercept) Injection for Patients with Wet AMD
Nov 27, 2017: Regeneron Provides Update on Eylea (Aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program
Oct 09, 2017: ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR
Sep 22, 2017: NICE gives EYLEA the Green Light for Treating Visual Impairment Due to mCNV
Aug 30, 2017: Bayer to showcase latest Ophthalmology research at EURETINA 2017
Jul 10, 2017: New use of drug could reduce need for laser treatment in diabetes
May 24, 2017: ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group Meeting in Budapest, Hungary
May 09, 2017: The first UK trial comparing intravitreal aflibercept and laser for proliferative diabetic retinopathy reports at ARVO 2017
Feb 02, 2017: Benitec Biopharma makes significant progress in ocular program
Jan 17, 2017: ONCURIOUS Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma
Jan 10, 2017: ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Alteogen Inc, H1 2018
Pipeline by Benitec Biopharma Ltd, H1 2018
Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2018
Pipeline by Coherus BioSciences Inc, H1 2018
Pipeline by Formycon AG, H1 2018
Pipeline by Lupin Ltd, H1 2018
Pipeline by Regeneron Pharmaceuticals Inc, H1 2018
Pipeline by ThromboGenics NV, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Alteogen Inc
Benitec Biopharma Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Coherus BioSciences Inc
Formycon AG
Lupin Ltd
Regeneron Pharmaceuticals Inc
ThromboGenics NV